回复：纳武利尤单抗联合伊匹木单抗对比舒尼替尼治疗晚期肾细胞癌 - Suppr

Suppr

超能文献

Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma.

作者信息

Powles Tom

机构信息

Barts Cancer Centre, Royal Free and St. Bartholomew's Hospitals, Queen Mary's University, London, UK.

出版信息

Eur Urol. 2018 Nov;74(5):679-680. doi: 10.1016/j.eururo.2018.07.019. Epub 2018 Aug 10.

DOI:10.1016/j.eururo.2018.07.019

PMID:30104083

Abstract

摘要

相似文献

Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma.回复：纳武利尤单抗联合伊匹木单抗对比舒尼替尼治疗晚期肾细胞癌

Eur Urol. 2018 Nov;74(5):679-680. doi: 10.1016/j.eururo.2018.07.019. Epub 2018 Aug 10.

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.纳武利尤单抗联合伊匹单抗作为晚期肾细胞癌一线治疗的成本效果分析。

J Immunother Cancer. 2018 Nov 20;6(1):124. doi: 10.1186/s40425-018-0440-9.

Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care.纳武利尤单抗联合伊匹单抗治疗转移性肾细胞癌的一线免疫治疗：一种新的治疗标准。

Cancer Biol Ther. 2019;20(1):6-7. doi: 10.1080/15384047.2018.1507260. Epub 2018 Oct 17.

Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.ccr-20-2063.

Eur Urol Oncol. 2020 Dec;3(6):804-805. doi: 10.1016/j.euo.2020.10.005. Epub 2020 Oct 26.

[Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].纳武利尤单抗联合伊匹木单抗对比舒尼替尼单药治疗——AUO的SUNNIFORECAST AN 41/16：一项针对既往未接受治疗的晚期（不可切除或转移性）非透明细胞肾细胞癌患者的2期随机开放标签研究

Urologe A. 2017 Jun;56(6):802-803. doi: 10.1007/s00120-017-0397-1.

[Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].

Gan To Kagaku Ryoho. 2019 Sep;46(9):1397-1404.

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial.转移性肾细胞癌的双重免疫检查点抑制：编者按：纳武利尤单抗联合伊匹木单抗与舒尼替尼用于晚期肾细胞癌一线治疗：III期CheckMate 214试验的4年延长随访

ESMO Open. 2021 Feb;6(1):100035. doi: 10.1016/j.esmoop.2020.100035. Epub 2021 Jan 7.

Should we use combination therapy for all advanced renal cell carcinoma?我们是否应该对所有晚期肾细胞癌患者采用联合治疗？

Lancet Oncol. 2019 Oct;20(10):1331-1332. doi: 10.1016/S1470-2045(19)30518-2. Epub 2019 Aug 16.

Kidney cancer: Antibody pincer movement challenges sunitinib as standard therapy.肾癌：抗体夹击疗法对舒尼替尼作为标准疗法构成挑战。

Nat Rev Urol. 2018 May;15(5):261. doi: 10.1038/nrurol.2018.47. Epub 2018 Apr 10.

[A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO].

Aktuelle Urol. 2020 Jun;51(3):236-238. doi: 10.1055/a-1079-7621. Epub 2020 Jun 2.

引用本文的文献

4E-BP3 deficiency impairs dendritic cell activation and CD4 T cell differentiation and attenuates α-myosin-specific T cell-mediated myocarditis in mice.4E-BP3 缺陷会损害树突状细胞的活化和 CD4 T 细胞的分化，并减轻小鼠中 α-肌球蛋白特异性 T 细胞介导的心肌炎。

Basic Res Cardiol. 2025 Feb;120(1):225-240. doi: 10.1007/s00395-024-01089-3. Epub 2024 Nov 9.

Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types.评估一种新型粪便微生物组检测方法的性能，该检测方法可预测多种癌症类型对一线免疫检查点抑制剂的反应。

Cancers (Basel). 2023 Jun 21;15(13):3268. doi: 10.3390/cancers15133268.

Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice.转移性肾细胞癌新型联合治疗方案的罕见且隐匿性毒性：真实实践中汲取的经验教训。

Curr Oncol. 2022 Sep 22;29(10):6776-6786. doi: 10.3390/curroncol29100533.

Renal Cell Carcinoma Associated With HIV/AIDS: A Review of the Epidemiology, Risk Factors, Diagnosis, and Treatment.与人类免疫缺陷病毒/获得性免疫综合征相关的肾细胞癌：流行病学、危险因素、诊断及治疗综述

Front Oncol. 2022 Apr 1;12:872438. doi: 10.3389/fonc.2022.872438. eCollection 2022.

Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy.卵巢癌的免疫细胞浸润图谱以鉴定预后及免疫治疗相关基因助力免疫治疗

Front Cell Dev Biol. 2021 Nov 3;9:749157. doi: 10.3389/fcell.2021.749157. eCollection 2021.

BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.BRDT 是肾细胞癌中 eIF4EBP1 的新型调节因子。

Oncol Rep. 2020 Dec;44(6):2475-2486. doi: 10.3892/or.2020.7796. Epub 2020 Oct 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验